<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20180623040206N1</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-07-17</date_registration>
      <primary_sponsor>Research and Technology Deputy of Guilan University of Medical Sciences.</primary_sponsor>
      <public_title>"Assessing the effect of applying local cold and hot pack on the bruising extent of Enoxaparin sodium injection site in patients admitted "</public_title>
      <acronym></acronym>
      <scientific_title>Assessing the effect of applying local cold and hot pack on the bruising extent of  Enoxaparin sodium injection site in patients admitted</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-07-10</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>74</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/32108</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Prevention, Randomization description: The samples size is 74. At first, the samples are selected by convenience sampling method and based on the inclusion criteria. Then, 37 subjects are allocated in the intervention group 1 (Local cold on the right side of the abdomen) and 37 in the intervention group 2 (Local cold- heat on the right side of the abdomen) based on the randomized blocking on a computer and obtaining a precise list in four block, Blinding description: Data on bruising is gathering through observing injection site for bruising and measuring its breadth by using a transparent millimeter ruler by  afellow trained researcher who does not know any information about injection methods.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Diseases of skin and subcutaneouse tissue.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group1: Samples(n=37) will receive per-filled syringe of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously after administration  on the right of the   abdomen,applying  a cold pack at a place of injection for 20 minutes with a temperature of 15 to 18 ° C. . The injection area will be identifying circled about 2/5 cm diameter by a waterproof pen, and then providing the education to patient about non-manipulation, including the lack of massage, scratching or touching the injection site. I n general, the investigator inject in two times in  each groups. The first injection on the right side of the abdomen is considered as an intervention and the second injection, which is performed 24 hours after the first injection on the left side of the abdomen, is considered as a control. There will be no intervention on the left side of the abdomen ( as control). Data on bruising is gathering through observing injection site for bruising and measuring its breadth by using a transparent millimeter ruler by  a fellow trained researcher who does not know any information about injection methods. The bruising extent is recorded in up to 3 days at 24, 48, 72 hours after injection (right and left side of the abdomen) in each groups and recorded in the data sheet. Intervention 2: Intervention group2: Samples(n=37) will receive per-filled syringe of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously after administration  on the right of the   abdomen,applying the cold pack for 20 minutes, 24 hours later, the warm pack with a temperature 40-43 ° C for 20 minutes is applied . The injection area will be identifying circled about 2/5 cm diameter by a waterproof pen, and then providing the education to patient about non-manipulation, including the lack of massage, scratching or touching the injection site. I n general, the investigator inject in two times in  each groups. The first injection on the right side of the abdomen is considered as an intervention and the second injection, which is performed 24 hours after the first injection on the left side of the abdomen, is considered as a control. There will be no intervention on the left side of the abdomen ( as control). Data on bruising is gathering through observing injection site for bruising and measuring its breadth by using a transparent millimeter ruler by  a fellow trained researcher who does not know any information about injection methods. The bruising extent is recorded in up to 3 days at 24, 48, 72 hours after injection (right and left side of the abdomen) in each groups and recorded in the data sheet.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
Total of data is Shareable after unidentifiable the people.

When:
Start the access period 6 months after printing the results

To whom:
Only for researchers working in academic and scientific institutions

Conditions:
Meta analysis

Where to obtain:
Ataollah Asadi Louyeh
Guilan University of Medical Sciences. Shahid Beheshti  Nursing and Midwifery School of Rasht

How to obtain:
contact by email

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ataollah asadi louyeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Daneshjoo street, Western Beheshti Boulvard, Beheshti nursing and midwifery college</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>39841-41469</zip>
        <telephone>+98 13 3355 5056</telephone>
        <email>aa.louyeh@gums.ac.ir</email>
        <affiliation>Guilan university of medical sciences,Beheshti nursing and midwifery college</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ataollah asadi louyeh</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Beheshti nursing and midwifery college, Daneshjoo street, Western Beheshti Boulvard</address>
        <city>Rasht</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>39841-41469</zip>
        <telephone>+98 13 3355 5056</telephone>
        <email>aa.louyeh@gums.ac.ir</email>
        <affiliation>Guilan university of medical sciences,Beheshti nursing and midwifery college</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>requiring hospital admission for at least 72 hours after receiving the second injection in the left abdomen
treatment with Enoxaparin sodium with a dose of 6000 units
having  the results of the latest coagulation tests include INR, PTT, PT in the range of therapy (up to 1.5-2.5 as normal), normal amounts of platelets and hematocrit
adequate renal function (creatinine 1.5-0.5 mg / dL)
lack of extensive skin lesions on the abdomen such as extensive scarring due to surgery or burn
lack of conditions preventing the correct implementation of the Enoxaparin injection method such as sever Ascites
abdominal bruises from the previous injection
satisfaction to participate in the research by signing a written consent</inclusion_criteria>
      <agemin>no limit</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>event of any change in the clinical condition is  required changing in the amount or discontinuation of the drug
performing subcutaneous injections Enoxaparin sodium on the right side of the abdomen by personnel
unwillingness to continue cooperation</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>XII</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>L00-L99</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Prevention</i_code>
      <i_code>Prevention</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group1: Samples(n=37) will receive per-filled syringe of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously after administration  on the right of the   abdomen,applying  a cold pack at a place of injection for 20 minutes with a temperature of 15 to 18 ° C. . The injection area will be identifying circled about 2/5 cm diameter by a waterproof pen, and then providing the education to patient about non-manipulation, including the lack of massage, scratching or touching the injection site. I n general, the investigator inject in two times in  each groups. The first injection on the right side of the abdomen is considered as an intervention and the second injection, which is performed 24 hours after the first injection on the left side of the abdomen, is considered as a control. There will be no intervention on the left side of the abdomen ( as control). Data on bruising is gathering through observing injection site for bruising and measuring its breadth by using a transparent millimeter ruler by  a fellow trained researcher who does not know any information about injection methods. The bruising extent is recorded in up to 3 days at 24, 48, 72 hours after injection (right and left side of the abdomen) in each groups and recorded in the data sheet.</i_keyword>
      <i_keyword>Intervention group2: Samples(n=37) will receive per-filled syringe of enoxaparin sodium 6000 IU (prepared by Alborzdarou company), subcutaneously after administration  on the right of the   abdomen,applying the cold pack for 20 minutes, 24 hours later, the warm pack with a temperature 40-43 ° C for 20 minutes is applied . The injection area will be identifying circled about 2/5 cm diameter by a waterproof pen, and then providing the education to patient about non-manipulation, including the lack of massage, scratching or touching the injection site. I n general, the investigator inject in two times in  each groups. The first injection on the right side of the abdomen is considered as an intervention and the second injection, which is performed 24 hours after the first injection on the left side of the abdomen, is considered as a control. There will be no intervention on the left side of the abdomen ( as control). Data on bruising is gathering through observing injection site for bruising and measuring its breadth by using a transparent millimeter ruler by  a fellow trained researcher who does not know any information about injection methods. The bruising extent is recorded in up to 3 days at 24, 48, 72 hours after injection (right and left side of the abdomen) in each groups and recorded in the data sheet.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The extent of bruising in area of Enoxaparin sodium in Milimeter. Timepoint: 24,48 and 72 hours after intervention. Method of measurement: Recording the bruising extent  based on multiplication of  the largest diameter in the smallest diameter (by flexible ruler in millimeter) in prepared form.</prim_outcome>
      <prim_outcome>The incidence of bruising in site of Enoxaparin sodium injection:discoloration in skin to violet color at least 2 mm. Timepoint: 24,48 and 72  hours after intervention. Method of measurement: Recording the observed bruising in prepared form by flexible ruler in millimeter)to measure skin discoloration.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome></sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Research and Technology Deputy of Guilan University of Medical Sciences.</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2018-06-11</approval_date>
        <contact_name>Ethics committee of Guilan University of Medical Sciences</contact_name>
        <contact_address>Eastern Shahid Beheshti Boulvard, Vice Chancellor for research of Guilan University of Medical Sciences Rasht Guilan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
